Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mallinckrodt plc
Siggi Olafsson has taken the reins at Mallinckrodt after stepping down as Hikma’s CEO. At the same time, Teva has named a new global R&D and chief medical officer while Piramal Pharma Solutions has appointed a fresh COO and Formycon has added to its supervisory board.
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
Keeping Track: US FDA Okays Alnylam’s siRNA Amvuttra, Alopecia Claim For Lilly’s Olumiant; Sierra Submits Momelotinib
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Craig Burton, who replaces the FDLI-bound Christine Simmon, tells the Pink Sheet that fighting rebating practices which harm insulin patients now can pave the way for successful launches of Humira biosimilars next year. Biosimilar markets should not be ‘winner-take-all,’ he says.
- Medical Devices
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Aspect Medical Systems, Inc.
- BÂRRX Medical, Inc.
- Cadence Pharmaceuticals, Inc.
- CNS Therapeutics, Inc.
- ev3 Inc.
- Given Imaging Ltd.
- Ikaria Holdings, Inc.
- InfaCare Pharmaceutical Corporation
- INO Therapeutics, LLC
- Mallinckrodt Inc.
- Mallinckrodt Pharmaceuticals
- Micro Therapeutics, Inc.
- Nellcor Puritan Bennett, Inc.
- Ocera Therapeutics Inc. (OCRX)
- Oridion Systems Ltd.
- Questcor Pharmaceuticals, Inc.
- Somanetics Corp.
- Sonorant Inc.
- SpecGx Inc.
- Sucampo Pharmaceuticals, Inc.(SCMP)
- VNUS Medical Technologies
- Stratatech Corporation
- Tranzyme Pharma